ARCHIVES

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

TA To Release Report On Burton Therapy Requested By Congress

February 9, 1990

Breast Asymmetry Predicts Breast Cancer, Study Finds

March 31, 2006

The Antineoplaston Anomaly: How A Drug Was Used For Decades In Thousands Of Patients, With No Safety, Efficacy Data

September 25, 1998

In Brief: Fabien Calvo named chief scientific officer of Cancer Core Europe

December 19, 2014

Trials Approved by NCI CTEP For the Month of March

March 30, 2012

Minority Accrual Low In Prevention Trials; NCI Plans Programs To Boost enrollment

February 2, 1996